Abstract

Prognosis of leukemia relapse post allogeneic stem cell transplantation (alloSCT) is poor and effective new treatments are urgently needed. T cells are pivotal in eradicating leukemia through a graft versus leukemia (GVL) effect and leukemia relapse is considered a failure of GVL. T-cell exhaustion is a state of T-cell dysfunction mediated by inhibitory molecules including programmed cell death protein 1 (PD-1) and T-cell immunoglobulin domain and mucin domain 3 (TIM-3). To evaluate whether T-cell exhaustion and inhibitory pathways are involved in leukemia relapse post alloSCT, we performed phenotypic and functional studies on T cells from peripheral blood of acute myeloid leukemia patients receiving alloSCT. Here we report that PD-1hiTIM-3+ cells are strongly associated with leukemia relapse post transplantation. Consistent with exhaustion, PD-1hiTIM-3+ T cells are functionally deficient manifested by reduced production of interleukin 2 (IL-2), tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ). In addition, these cells demonstrate a phenotype consistent with exhausted antigen-experienced T cells by losing TN and TEMRA subsets. Importantly, increase of PD-1hiTIM-3+ cells occurs before clinical diagnosis of leukemia relapse, suggesting their predictive value. Results of our study provide an early diagnostic approach and a therapeutic target for leukemia relapse post transplantation.

Highlights

  • Leukemia relapse remains the top cause of death post allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia (AML).[1]

  • We report that PD-1hiTIM-3+ cells are strongly associated with leukemia relapse post transplantation

  • It has been reported that several receptors including B- and T-lymphocyte attenuator (BTLA), 2B4, lymphocyteactivation gene 3 (LAG-3), CD160, T-cell immunoglobulin domain and mucin domain 3 (TIM-3) and PD-1 are upregulated on the T-cell surface to mediate T-cell exhaustion in a variety of tumors.[18]

Read more

Summary

Introduction

Leukemia relapse remains the top cause of death post allogeneic hematopoietic stem cell transplantation (alloSCT) in patients with acute myeloid leukemia (AML).[1]. General management includes withdrawal of immune suppressors, reinduction chemotherapy, donor lymphocyte infusion and second transplantation.[4,5,6,7,8,9,10,11] None of these approaches are very effective. Instead, they all carry some degree of risk such as graft versus host disease (GVHD), severe infections and multiorgan failure. There is no ‘standard care’ for patients with AML relapse post alloSCT and clinical practice is largely per physician’s choice.

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.